PharmTech Weekly Roundup—June 5, 2026

Three themes drove the headlines this week: regulatory reform, patient access, and supply chain security.

From the FDA and the European Medicines Agency (EMA) to the International Council for Harmonisation (ICH) and the US Pharmacopeia (USP), standards are being rewritten across biologics, biosimilars, and gene therapies, and that's changing how manufacturers build their development programs.

Whether it's affordable GLP-1s in Canada, inhaled insulin for children, or radiopharmaceuticals for oncology patients, the pressure to get more therapies to more patients, at lower cost, is front and center.

From Delaware's reshoring push to global Ebola response, the question of where medicines are made—and who controls that—has never been more urgent.

In news this week, the EMA, the African Medicines Agency, and national regulators across Africa launched the first joint regulatory collaboration to fast-track clinical trials and countermeasures for the active Ebola outbreak in the DRC and Uganda—a virus for which no authorized vaccines or treatments currently exist.

The US Pharmacopeia has released its first set of product-specific biologics standards and invited stakeholders to comment on a framework designed to reduce regulatory variability and accelerate market access for biologics and biosimilars.

The FDA issued new draft guidance allowing sponsors to leverage existing CMC, nonclinical, and clinical platform knowledge—including published literature, master files, and consortium data—in gene therapy submissions, aiming to cut development costs and timelines for patients with rare and life-threatening diseases without compromising safety standards.

The FDA's approval of inhaled insulin for children aged six and older signals growing momentum for dry powder biologic delivery—but also underscores the significant manufacturing complexity involved, including precision particle engineering, specialized facility design, and a distinct regulatory documentation burden that developers must plan for early.

PharmTech’s editors were at CPHI Americas in Philadelphia this week, where Delaware Governor Matt Meyer made the case that domestic pharmaceutical manufacturing is a national security imperative—not just an economic one— and positioned Delaware's streamlined regulatory environment as the fastest, lowest-cost destination for reshoring production.

Delaware's biopharma strategy—anchored in public-private collaboration, expedited permitting, continuous manufacturing investment, and early-stage STEM workforce development—offers a scalable model for governments and industry seeking to accelerate drug development and domestic manufacturing.

Former FDA Oncology Center of Excellence Director Richard Pazdur also spoke at CPHI Americas, where he warned that staff turnover and inconsistent review standards at the FDA are creating a less predictable regulatory environment — and called for modernized Special Protocol Assessments, real-time oncology review, and stronger advisory committee practices to restore sponsor confidence.

On PharmTech.com this week, industry consultant, Ajoy Koppolu, explained how repurposing off-patent generics offers pharma companies a low-risk, faster path to cancer pipeline expansion by leveraging established safety profiles and existing manufacturing infrastructure.

Kimberly Salgado of ICON discussed how new FDA and EMA guidance streamlines biosimilar development by reducing the need for comparative efficacy studies when analytical similarity is robustly demonstrated—but this shift places significantly greater demands on analytical characterization, PK studies, and bioanalytical rigor, while intensifying global competition.

Dr. Reddy's Laboratories’ CEO provided insight on the company’s generic semaglutide injection that was approved in Canada in May—making it the first G7 country to authorize a GLP-1 generic—signaling a pivotal inflection point for manufacturers with integrated peptide synthesis capabilities as patent exclusivities erode across major markets.

ICON’s John Muganga explained how the 2024 implementation of ICH Q5A(R2) modernizes viral safety for biologics manufacturing by formalizing next-generation sequencing for adventitious agent detection, introducing continuous manufacturing provisions, and enabling platform prior-knowledge approaches—giving CMC teams concrete tools to shorten testing timelines while strengthening safety assurance.

And finally, Nicolas Richardson of Precision for Medicine talked about how successful radiopharmaceutical development requires a site strategy built around nuclear medicine-ready centers of excellence and isotope pairs that support scalable just-in-time delivery.

Regulatory modernization, patient access, and supply chain security are the threads connecting this week's stories. The decisions being made right now in guidance documents, state legislatures, and manufacturing facilities will shape the industry for years to come. Be sure to watch the interviews and read the articles on PharmTech.com.